As shown in Figures 9C–E, high expression of ADAMTS14 had a higher TIDE score, a higher T-cell dysfunction score, and a lower MSI score, indicating that these patients might have a lower efficacy and worse outcome after accepting the immunotherapy than ccRCC patients with low expression of ADAMTS14. Here, ADAMTS14 is linked to nonpapillary renal cell carcinoma.